<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543387</url>
  </required_header>
  <id_info>
    <org_study_id>5108-001</org_study_id>
    <secondary_id>2007_598</secondary_id>
    <nct_id>NCT00543387</nct_id>
  </id_info>
  <brief_title>Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4)</brief_title>
  <official_title>A Phase I Investigation of MK-5108 and MK-5108 With Docetaxel in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, side effects and how well the body tolerates MK-5108
      as well as determine different doses of MK-5108 in participants with advanced and/or
      refractory solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experience an adverse event</measure>
    <time_frame>From Day 1 of study treatment until 30 days following the last dose of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Day 1 to Day 21 of study treatment (Cycle 1)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Cancer, Neoplasms, Tumors</condition>
  <arm_group>
    <arm_group_label>MK-5108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants entered into the MK-5108 group (Panel 1) will receive MK-5108 as monotherapy; MK-5108 will be administered to cohorts of participants in sequentially rising doses. MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-5108 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MK-5108 + Docetaxel group (Panel 2) will receive MK-5108 in combination with an intravenous (I.V.) dose of docetaxel (60 mg/m^2). MK-5108 will be administered to cohorts of participants in sequentially rising doses. MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 21 days in Panel 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5108</intervention_name>
    <description>MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.</description>
    <arm_group_label>MK-5108</arm_group_label>
    <arm_group_label>MK-5108 + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>intravenous (I.V.) dose of docetaxel (60 mg/m^2)</description>
    <arm_group_label>MK-5108 + Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Participant has a histologically-confirmed metastatic or locally advanced solid tumor
        that has failed to respond to standard therapy or progressed with standard therapy

        Exclusion Criteria:

          -  Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks
             prior to study start or has not recovered from adverse events caused by therapy more
             than 4 weeks earlier

          -  Participant is currently participating or has participated in a study with an
             investigational compound or device within 4 weeks prior to signing informed consent

          -  Participant has received more than 2 courses of chemotherapy for metastatic disease

          -  Participant has had prolonged neutropenia or neutropenia with fever from previous
             chemotherapy treatment

          -  Participant has a primary central nervous system tumor

          -  Participant is a regular or recreational user of any illicit drugs or has a recent
             history within the last year of drug or alcohol abuse

          -  Participant is pregnant, breastfeeding or planning to have children during the study

          -  Participant is Human Immunodeficiency Virus (HIV) positive

          -  Participant has a history of Hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Invest New Drugs. 2016 Feb;34(1):84-95. doi: 10.1007/s10637-015-0306-7. Epub 2015 Dec 1.</citation>
    <PMID>26620496</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 19, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

